

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 June 2018 (21.06.2018)



(10) International Publication Number
WO 2018/111012 A1

(51) International Patent Classification:

C07D 417/12 (2006.01) C07D 417/14 (2006.01)

C07D 417/10 (2006.01) A61K 31/541 (2006.01)

(21) International Application Number:

PCT/KR2017/014757

(22) International Filing Date:

14 December 2017 (14.12.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10-2016-0171541 15 December 2016 (15.12.2016) KR

10-2017-0171228 13 December 2017 (13.12.2017) KR

(71) Applicant: IL DONG PHARMACEUTICAL CO., LTD.

[KR/KR]; 2, Baumoe-ro 27-gil, Seocho-gu, Seoul 06752 (KR).

(72) Inventors: KANG, Jae-Hoon; 407, 23, Gangnam-daero

61-gil, Seocho-gu, Seoul 06616 (KR). LEE, Hong-Sub; 108-1402, 21-11, Gugal-ro 28beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 16973 (KR). AN, Kyung-Mi; 301-1404, 16, Samseong-ro 59beon-gil, Gunpo-si, Gyeonggi-do 15873 (KR). HONG, Chang-Hee; 102-1302, 637, Yangcheon-ro, Gangseo-gu, Seoul 07544 (KR). KWAK, Hyun-Jung; 205-501, 39, Seryu-ro, Gwonseon-gu, Suwon-si, Gyeonggi-do 16592 (KR). CUI, Shuo-Lin; 104-1702, 264, Dongtanbanseok-ro, Hwaseong-si, Gyeonggi-do 18452 (KR). SONG, Hyo-Jung; 102-305, 38, Mok-dongjungangbuk-ro, Yangcheon-gu, Seoul 07949 (KR).

(74) Agent: LEE, Myoung-Jin; 6th floor, 28, Yeongdong-daero

85-gil, Gangnam-gu, Seoul 06180 (KR).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

WO 2018/111012 A1

(54) Title: NOVEL PHENYL PROPIONIC ACID DERIVATIVES AND USES THEREOF

(57) Abstract: The present invention relates to the compounds according to Formula (I), the racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions comprising these, for the treatment or prevention of metabolic disorders. The compounds according to Formula (I) are, as GPR40 agonists, available for oral administration with glucose-dependent insulin secretion mechanism, which exhibit excellent glucose lowering efficacy without the risk of hypoglycemia. Thus, the compounds and/or pharmaceutical compositions comprising the compounds as effective components are useful in treating and/or preventing symptoms of type 2 diabetes through adequate control of blood glucose.